Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux sodium for venous thromboembolism prophylaxis after total hip or knee arthroplasty
ChiCTR2300067693Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Feb 2023
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fondaparinux in venous thromboembolism (VTE), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: VTE rate, Bleeding events and 1 more. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2300067693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067693.